A promising candidate antibiotic, called teixobactin and originating from soil bacteria, potently kills pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae and shows no signs of antibiotic resistance, according to Slava Epstein and Kim Lewis at Northeastern University in Boston, Mass. It is one among some 25 antimicrobial or antitumor compounds that their collaborators at NovoBiotic Pharmaceuticals in nearby Cambridge managed to extract recently from soil microbes that tend to be diffıcult to culture, they say. Details appeared 22 January 2015 in Nature (doi:10.1038/nature14098).
The soil bacterium Eleftheria terrae, recovered from a grassy fıeld in Maine, makes teixobactin, whose name derives from the Greek word teixo, meaning wall and reflecting the compound's ability to target bacterial cell walls. Teixobactin, which acts on gram-positive bacteria, binds to Lipid II, a precursor of peptidoglycan, the main cell wall matrix, and Lipid III, a precursor of teichoic acids, which attach and add to the strength of the cell wall in such bacteria. The molecule is "an unusual depsipeptide which contains enduracididine, methylphenylalanine, and four D-amino acids," Lewis, Epstein, and their collaborators note. It does not target proteins, DNA, or RNA.
Teixobactin protects mice against otherwise lethal MRSA and S. pneumoniae infections, according to Lewis and Epstein. The protective dose of teixobactin is similar to that for vancomycin, an antibiotic being used widely to treat drug-resistant infections in humans. Vancomycin, which took 30 years to show resistance, also targets lipid II.
The dual mode of action of teixobactin against nonprotein targets reduces the odds of pathogens developing resistance against it, according to Lewis. "Resistance arises quickly in protein targets," he says. "It's more diffıcult for a cell to come up with mutations to modify lipids. Teixobactin is an example of a compound that evolved to be largely free of resistance."
"If the odds of developing resistance to a single target is one in a thousand, and the second target has similar odds, then the chance of resistance to both targets occurring at the same time is one in a million," says microbiologist William Metcalf of the University of Illinois, Urbana. A cell would have to mutate both targets simultaneously, "and that's a very diffıcult thing to do."
The approach that Lewis and Epstein developed for recovering compounds from diffıcult-to-cultivate microorganisms is "a clever way to get organisms that have not previously been cultivated to make antibiotics," he adds.
More than a decade ago, Lewis, Epstein, and their collaborators designed a diffusion chamber for recovering and studying microorganisms that are diffıcult to culture in the lab. Since then, the diffusion chamber was redesigned and replaced with the iChip, an array of miniaturized chambers that allow for parallel cultivation of such microbes, according to Epstein. "We've grown 10,000 soil microbes and obtained novel antimicrobial compounds from them," he says. "We lose 75% of what grows in nature, yet we get so much more than we could obtain using standard lab approaches."
Although teixobactin looks promising at this stage, it could fail during The iChip® device, which was used to sample and cultivate thousands of microorganisms leading to the isolation of teixobactin, an antimicrobial agent that makes development of resistance extremely unlikely. (Photo courtesy of Slava Epstein. Antibodies, particularly neutralizing antibodies that block viral interactions with host cells, can prevent infections. However, while humans make many antibodies against Ebola, most are unable to protect the host from the virus, according to Saphire. The virus hides from them beneath a glycan cap, which is removed when the virus enters cells. "Antibodies against the mucin-like domains of the glycoprotein (GP) are generally non-neutralizing because these domains, and antibodies bound to them, are stripped from the viral surface by host cathepsins in endosomes, leaving behind an antibody-free, functional receptorbinding core," she says.
Rarely, humans and animals generate protective antibody responses against Ebola virus, thereby surviving infections. ZMapp is a mixture of such antibodies that was used to treat some patients during the 2014 -2015 Ebola outbreak in West Africa with partial success. This mixture and earlier formulations also are effective in treating rodents or nonhuman primates infected by Ebola. The ongoing outbreak amassed close to 24,000 cases and caused nearly 10,000 deaths as of March 2015, according to estimates from the Centers for Disease Control and Prevention in Atlanta, Ga.
Two of the antibodies within these mixtures, despite binding the mucinlike domain glycan cap of Ebola virus, confer some protection to hosts, possibly by recruiting immune effector functions, Saphire says. "Perhaps those non-neutralizing antibodies that are nonetheless protective bind surfaceexpressed GP and facilitate immune responses, such as antibody-dependent cellular cytotoxicity or complement." However, those two types of antibodies could be more effective if accompanied by additional partners with neutralizing capabilities, Saphire continues. ZMapp contains such neutraliz- 
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